Table 2.
CSF neurotransmitter metabolites.
| Metabolite (normal range) | Baseline | Month 3 | Month 6 | Month 12 | Month 24 | |
|---|---|---|---|---|---|---|
| BL1 | BL2 | |||||
| HVA (218–852 nmol/L) | ||||||
| Subject 1 | <5 | 15 | 49 | 59 | 52 | 12 |
| Subject 2 | 18 | 10 | 66 | 56 | 52 | 73 |
| Subject 3 | 12 | 14 | 71 | 89 | 103 | 137 |
| Subject 4 | 10a | 7 | 12 | 75 | 57 | – |
| Subject 5 | 12 | 11 | 76 | 70 | 59 | – |
| Subject 6 | 5 | 8 | 134 | 138 | – | – |
| Subject 7 | 37 | 38 | 172 | 146 | – | – |
| 5-HIAA (66–338 nmol/L) | ||||||
| Subject 1 | 10 | 7 | <5 | <5 | 7 | <5 |
| Subject 2 | <5 | <5 | <5 | <5 | <5 | 8 |
| Subject 3 | 5 | <5 | <5 | <5 | 7 | 24 |
| Subject 4 | <5 | <5 | 13 | 25 | <5 | – |
| Subject 5 | 21 | <5 | <5 | 8 | <5 | – |
| Subject 6 | <5 | 5 | 12 | 6 | – | – |
| Subject 7 | 5 | 42 | 26 | 14 | – | – |
| 3-OMD (<100 nmol/L) | ||||||
| Subject 1 | 605 | 600 | 504 | 549 | 875 | 443 |
| Subject 2 | 719 | 556 | 489 | 410 | 368 | 460 |
| Subject 3 | 378 | 358 | 443 | 413 | 303 | 432 |
| Subject 4 | 2104a | 578 | 517 | 426 | 441 | – |
| Subject 5 | 343 | 529 | 379 | 632 | 625 | – |
| Subject 6 | 429 | 411 | 446 | 325 | – | – |
| Subject 7 | 928 | 769 | 558 | 556 | – | – |
HVA homovanillic acid, 5-HIAA 5-hydroxyindoleacetic acid, 3-OMD 3-O-methyldopa.
aSubject 4 was taking carbidopa-levodopa at the time of the first baseline lumbar puncture. The medication was tapered off prior to the day of surgery (2nd baseline lumbar puncture).